Retraction Note: Cancer Cell International (2020) 20:592
The Editor in Chief has retracted this article. Following publication concerns were raised regarding a number of figures, including but not limited to:
-
The TMZ 0hr panel in Fig. 2a appears similar to the FDPs 0h panel in Fig. 3 in [1] and the BRD4-KO#1 0h panel in Fig. 2C in [2].
-
The Vector and CtBP1 bands in Fig. 3B appear similar to U251 Vector and b-catenin bands in Fig. 6G in [3] and p62 and b-actin blots in Fig. 3B in [4].
-
The p-62 u87/TMZ-R in Fig. 3E appears similar to the Mcl-1 CHX blot in Fig. 4C in [5] and the p-PI3K GIST430 in [2].
The Editor-in-Chief therefore no longer has confidence in the results and conclusions of this article. The authors did not state explicitly whether they agree to this retraction.
References
Chen Z, Chen G, Zhao H. FDPS promotes glioma growth and macrophage recruitment by regulating CCL20 via Wnt/β-catenin signalling pathway. J Cell Mol Med. 2020;24(16):9055–66. https://doi.org/10.1111/jcmm.15542.
Mu J, Sun P, Ma Z, Sun P. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours. J Cell Mol Med. 2020;24(4):2519–30. https://doi.org/10.1111/jcmm.14945.
Tian T, Guo T, Zhen W, Zou J, Li F. BET degrader inhibits tumor progression and stem-like cell growth via Wnt/β-catenin signaling repression in glioma cells. Cell Death Dis. 2020;11(10):1–13. https://doi.org/10.1038/s41419-020-03117-1.
Wang Z, Zhao Y, Xu H, Liang F, Zou Q, Wang C, Lin F. CtBP1 promotes tumour-associated macrophage infiltration and progression in non–small‐cell lung cancer. J Cell Mol Med. 2020;24(19):11445–56. https://doi.org/10.1111/jcmm.15751.
Lin L, Ding D, Xiao X, Li B, Cao P, Li S. (2020). Trametinib potentiates TRAIL-induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells. Journal of Cellular and Molecular Medicine, 24(12), 6822–6832. https://doi.org/10.1111/jcmm.15336
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12935-020-01693-y.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Qu, H., Song, X., Song, Z. et al. Retraction Note: Berberine reduces temozolomide resistance by inducing autophagy via the ERK1/2 signaling pathway in glioblastoma. Cancer Cell Int 24, 202 (2024). https://doi.org/10.1186/s12935-024-03394-2
Accepted:
Published:
DOI: https://doi.org/10.1186/s12935-024-03394-2